In the latest report, overall survival (OS) outcomes favored pembrolizumab versus chemotherapy as first-line therapy regardless of the PD-L1 tumor proportion score (TPS) (hazard ratio for TPS ≥ 50%, 0.68; TPS ≥ 20%, 0.75; TPS ≥ 1%, 0.79), with estimated 5-year OS rates with pembrolizumab of 21.9%, 19.4%, and 16.6%, respectively, compared to an OS of 5.5% achieved with cytotoxic chemotherapies before the advent of immunotherapy [3]. This evidence concerns the gene CD274 and neoplasm.